Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENT trial of taldefgrobep alfa in spinal muscular atrophy
NL-OMON53477Phase 3Recruiting
- Sponsor
- Biohaven Ltd.
- Start
- Apr 2023
- Modality
- Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of taldefgrobep alfa in spinal muscular atrophy (SMA) (3 arms), sponsored by Biohaven Ltd. Started Apr 2023; status: recruiting.
02
Drugs
taldefgrobep alfa
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON53477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53477.